Sutent for meningioma – pro
The first prospective trial to demonstrate efficacy of a medical treatment for patients with aggressive meningioma with Sutent was recently completed, It concluded that the rate of progression-free survival seen with this regimen “warrants further investigation.”
NCCN lists Sunitinib as category 2B NCCN also lists interferon and a a somatastatin analogue, if octreotide scan positive. Both fo these are Category 2B recommendations.
Thomas J. Kaley Patrick Wen David Schiff Keith Ligon Sam Haidar Sasan Karimi Andrew B. Lassman Craig P. Nolan Lisa M. DeAngelis Igor Gavrilovic. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology, Volume 17, Issue 1, 1 January 2015, Pages 116121
NCCN, Meningioma BRAIN-D, 2017